


# Human Tissue Microarray - iCon (internal control) TMA® MUC-1

REF / Cat.-No.: 401 5222

Lot: 121iC

Label	Tissue type control tissue: mamma-carcinoma
	spot 1: strong positive spot 2: moderate spot 3: moderate spot 4: negative
Free Space for your tissue under investigation	

### Technical Information:

- Spot diameter: 1.5 mm
- Paraffin embedded tissue
- Fixation in 4 % paraformaldehyde in PBS
- Slide Material: Standard: Superfrost® Plus.

**For Handling Instruction please see our iCon® TMA Product Sheet or contact our customer service.**

### Antibody / Marker description:

This gene is a member of the mucin family and encodes a membrane bound, glycosylated phosphoprotein. The protein is anchored to the apical surface of many epithelia by a transmembrane domain (EMA-epithelial membrane antigen), with the degree of glycosylation varying with cell type. It also includes a 20 aa variable number tandem repeat (VNTR) domain, with the number of repeats varying from 20 to 120 in different individuals. The protein serves a protective function by binding to pathogens and also functions in a cell signaling capacity. Overexpression, aberrant intracellular localization, and changes in glycosylation of this protein have been associated with carcinomas. Multiple alternatively spliced transcript variants that encode different isoforms of this gene have been reported, but the full-length nature of only some has been determined.

### Literature:

- Peterson JA, Scallan CD, Ceriani RL, Hamosh M (2002). "Structural and functional aspects of three major glycoproteins of the human milk fat globule membrane.". *Adv. Exp. Med. Biol.* **501**: 179-87
- Leroy X, Buisine MP, Leteurtre E, et al. (2007). "[MUC1 (EMA): A key molecule of carcinogenesis?]. *Annales de pathologie* **26** (4): 257-66.
- Li Y, Cozzi PJ (2007). "MUC1 is a promising therapeutic target for prostate cancer therapy". *Current cancer drug targets* **7** (3): 259-71
- Leroy X, Buisine MP, Leteurtre E, et al. (2007). "[MUC1 (EMA): A key molecule of carcinogenesis?]. *Annales de pathologie* **26** (4): 257-66
- Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006). "International Union of Pharmacology. LXIV. Estrogen receptors". *Pharmacol. Rev.* **58** (4): 773-81.
- Deroo BJ, Korach KS (2006). "Estrogen receptors and human disease". *J. Clin. Invest.* **116** (3): 561-70.
- Fabian CJ, Kimler BF (2005). "Selective estrogen-receptor modulators for primary prevention of breast cancer". *J. Clin. Oncol.* **23** (8): 1644-55.
- Ascenzi P, Bocedi A, Marino M (August 2006). "Structure-function relationship of estrogen receptor alpha and beta: impact on human health". *Mol Aspects Med* **27** (4): 299-402.
- Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC (2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". *Endocrinology* **144** (10): 4241-9

## FOR INTERNAL QUALITY CONTROL . RESEARCH USE ONLY.

### Your expert in target validation



Vorstandsvorsitzender: Dr. Manrico Paulitschke  
 Aufsichtsratsvorsitzender: Bernd Hartmann  
 Bankverbindung: Weberbank  
 IBAN: DE82 1012 0100 1003 0775 82  
 BIC: WELADED1WBB

Steuer-Nr.: 37/164/21415  
 USt-ID-Nr.: DE 218 804 519  
 Handelsregister: HRB 82258  
 AG Berlin-Charlottenburg